Daclatasvir, Asunaprevir, and Beclabuvir Shows High Cure Rates for People with Genotype 1 Hepatitis C
- Category: Experimental HCV Drugs
- Published on Wednesday, 13 May 2015 00:00
- Written by Liz Highleyman
A twice-daily fixed-dose coformulation of daclatasvir, asunaprevir, and beclabuvir taken for 12 weeks cured 91% of genotype 1 chronic hepatitis C patients without liver cirrhosis, and even higher sustained response rates were obtained for people with cirrhosis when ribavirin was added, according to findings from the Phase 3 UNITY studies published in the May 5 issue of JAMA.